26
|
Gurny R. Editorial from the outgoing Editor. Eur J Pharm Biopharm 2013; 85:327. [PMID: 24184804 DOI: 10.1016/j.ejpb.2013.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Mulinacci F, Poirier E, Capelle MA, Gurny R, Arvinte T. Influence of methionine oxidation on the aggregation of recombinant human growth hormone. Eur J Pharm Biopharm 2013; 85:42-52. [DOI: 10.1016/j.ejpb.2013.03.015] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2012] [Revised: 03/14/2013] [Accepted: 03/19/2013] [Indexed: 10/26/2022]
|
28
|
Rodriguez-Aller M, Guillarme D, El Sanharawi M, Behar-Cohen F, Veuthey JL, Gurny R. In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application. J Control Release 2013; 170:153-9. [DOI: 10.1016/j.jconrel.2013.04.019] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2012] [Revised: 04/21/2013] [Accepted: 04/28/2013] [Indexed: 01/08/2023]
|
29
|
Westermaier Y, Veurink M, Riis-Johannessen T, Guinchard S, Gurny R, Scapozza L. Identification of aggregation breakers for bevacizumab (Avastin®) self-association through similarity searching and interaction studies. Eur J Pharm Biopharm 2013; 85:773-80. [PMID: 23665445 DOI: 10.1016/j.ejpb.2013.04.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Revised: 04/16/2013] [Accepted: 04/19/2013] [Indexed: 10/26/2022]
Abstract
Aggregation is a common challenge in the optimization of therapeutic antibody formulations. Since initial self-association of two monomers is typically a reversible process, the aim of this study is to identify different excipients that are able to shift this equilibrium to the monomeric state. The hypothesis is that a specific interaction between excipient and antibody may hinder two monomers from approaching each other, based on previous work in which dexamethasone phosphate showed the ability to partially reverse formed aggregates of the monoclonal IgG1 antibody bevacizumab back into monomers. The current study focuses on the selection of therapeutically inactive compounds with similar properties. Adenosine monophosphate, adenosine triphosphate, sucrose-6-phosphate and guanosine monophosphate were selected in silico through similarity searching and docking. All four compounds were predicted to bind to a protein-protein interaction hotspot on the Fc region of bevacizumab and thereby breaking dimer formation. The predictions were supported in vitro: An interaction between AMP and bevacizumab with a dissociation constant of 9.59±0.15 mM was observed by microscale thermophoresis. The stability of the antibody at elevated temperature (40 °C) in a 51 mM phosphate buffer pH 7 was investigated in presence and absence of the excipients. Quantification of the different aggregation species by asymmetrical flow field-flow fractionation and size exclusion chromatography demonstrates that all four excipients are able to partially overcome the initial self-association of bevacizumab monomers.
Collapse
|
30
|
Walpoth BH, Mugnai D, de Valence S, Mrowczynski W, Tille JC, Montet X, Gurny R, Kalangos A, Moeller M. Comparison of synthetic small-calibre biodegradable vs. stable ePTFE vascular prosthesis after long-term implantation in the rat aorta. Cardiovasc Pathol 2013. [DOI: 10.1016/j.carpath.2013.01.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
31
|
Vacher G, Kaeser MD, Moser C, Gurny R, Borchard G. Recent Advances in Mucosal Immunization Using Virus-like Particles. Mol Pharm 2013; 10:1596-609. [DOI: 10.1021/mp300597g] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
32
|
Kasimova AO, Pavan GM, Danani A, Mondon K, Cristiani A, Scapozza L, Gurny R, Möller M. Validation of a Novel Molecular Dynamics Simulation Approach for Lipophilic Drug Incorporation into Polymer Micelles. Chimia (Aarau) 2013. [DOI: 10.2533/chimia.2013.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
33
|
Asmus LR, Tille JC, Kaufmann B, Melander L, Weiss T, Vessman K, Koechling W, Schwach G, Gurny R, Möller M. In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer. J Control Release 2013; 165:199-206. [DOI: 10.1016/j.jconrel.2012.11.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2012] [Revised: 11/22/2012] [Accepted: 11/25/2012] [Indexed: 10/27/2022]
|
34
|
Walpoth BH, Mugnai D, de Valence S, Mrowczynski W, Tille JC, Montet X, Gurny R, Moeller M, Kalangos A. Non-inferiority of synthetic small-calibre biodegradable vs. stable ePTFE vascular prosthesis after long-term implantation in the rat aorta. Thorac Cardiovasc Surg 2013. [DOI: 10.1055/s-0032-1332295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
35
|
Gurny R, Möller M. Editorial. Eur J Pharm Biopharm 2013. [DOI: 10.1016/j.ejpb.2012.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
de Valence S, Tille JC, Giliberto JP, Mrowczynski W, Gurny R, Walpoth B, Möller M. Advantages of bilayered vascular grafts for surgical applicability and tissue regeneration. Acta Biomater 2012; 8:3914-20. [PMID: 22771455 DOI: 10.1016/j.actbio.2012.06.035] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2012] [Revised: 06/12/2012] [Accepted: 06/25/2012] [Indexed: 10/28/2022]
Abstract
Nanofibrous scaffolds are part of an intense research effort to design the next generation of vascular grafts. With electrospinning, the production of micro- and nano-fiber-based prostheses is simple and cost effective. An important parameter for tissue regeneration in such scaffolds is pore size. Too small pores will impede cell infiltration, but too large pores can lead to problems such as blood leakage. In this study, bilayered grafts were made by electrospinning a high-porosity graft with a low-porosity layer on either the luminal or the adventitial side. Grafts were characterized in vitro for fiber size, pore size, total porosity, water and blood leakage, mechanical strength, burst pressure and suture retention strength, and were evaluated in vivo in the rat abdominal aorta replacement model for 3 and 12 weeks. In vitro blood leakage through these bilayered grafts was significantly reduced compared with a high-porosity graft. All grafts had an excellent in vivo outcome, with perfect patency and no thrombosis. Cell invasion and neovascularization were significantly reduced in the grafts with a low-porosity layer on the adventitial side, and there was no significant difference between the grafts in endothelialization rate or intimal hyperplasia. By tailoring the microarchitecture of biodegradable vascular prostheses, it is therefore possible to optimize the scaffold for tissue regeneration while preventing blood leakage, and thus facilitating applicability in the clinic.
Collapse
|
37
|
Patois E, Larmour I, Bell S, Palais C, Capelle M, Gurny R, Arvinte T. Ultraviolet Resonance Raman spectroscopy used to study formulations of salmon calcitonin, a starch–peptide conjugate and TGF-β3. Eur J Pharm Biopharm 2012; 81:392-8. [DOI: 10.1016/j.ejpb.2012.02.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2011] [Revised: 01/27/2012] [Accepted: 02/27/2012] [Indexed: 10/28/2022]
|
38
|
Di Tommaso C, Valamanesh F, Miller F, Furrer P, Rodriguez-Aller M, Behar-Cohen F, Gurny R, Möller M. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. Invest Ophthalmol Vis Sci 2012; 53:2292-9. [PMID: 22427552 DOI: 10.1167/iovs.11-8829] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
PURPOSE The aim of the present study was the in vitro and in vivo evaluation of a novel aqueous formulation based on polymeric micelles for the topical delivery of cyclosporine A for dry eye treatment. METHODS In vitro experiments were carried out on primary rabbit corneal cells, which were characterized by immunocytochemistry using fluorescein-labeled lectin I/isolectin B4 for the endothelial cells and mouse monoclonal antibody to cytokeratin 3+12 for the epithelial ones. Living cells were incubated for 1 hour or 24 hours with a fluorescently labeled micelle formulation and analyzed by fluorescence microscopy. In vivo evaluations were done by Schirmer test, osmolarity measurement, CyA kinetics in tears, and CyA ocular distribution after topical instillation. A 0.05% CyA micelle formulation was compared to a marketed emulsion (Restasis). RESULTS The in vitro experiments showed the internalization of micelles in the living cells. The Schirmer test and osmolarity measurements demonstrated that micelles did not alter the ocular surface properties. The evaluation of the tear fluid gave similar CyA kinetics values: AUC = 2339 ± 1032 min*μg/mL and 2321 ± 881.63; Cmax = 478 ± 111 μg/mL and 451 ± 74; half-life = 36 ± 9 min and 28 ± 9 for the micelle formulation and Restasis, respectively. The ocular distribution investigation revealed that the novel formulation delivered 1540 ± 400 ng CyA/g tissue to the cornea. CONCLUSIONS The micelle formulation delivered active CyA into the cornea without evident negative influence on the ocular surface properties. This formulation could be applied for immune-related ocular surface diseases.
Collapse
|
39
|
Kasimova AO, Pavan GM, Danani A, Mondon K, Cristiani A, Scapozza L, Gurny R, Möller M. Validation of a novel molecular dynamics simulation approach for lipophilic drug incorporation into polymer micelles. J Phys Chem B 2012; 116:4338-45. [PMID: 22435641 DOI: 10.1021/jp2104819] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Polymer micelles can be used to facilitate the aqueous solubilization of lipophilic, poorly water-soluble compounds and drugs. Even if the evaluation of the efficiency of drug incorporation into such micelles can be tested experimentally, a theoretical approach based on molecular simulation can constitute a useful tool that reduces time and cost. Here we present a promising method, based on molecular dynamics simulation, for the calculation of the Flory-Huggins interaction parameters as a measure of the potential for drug incorporation into polymer micelles. The data from modeling are validated on four drug compounds with different physical-chemical properties by means of a comparison with the data obtained from experiments.
Collapse
|
40
|
Rodriguez-Aller M, Kaufmann B, Guillarme D, Stella C, Furrer P, Rudaz S, El Zaoui I, Valamanesh F, Di Tommaso C, Behar-Cohen F, Veuthey JL, Gurny R. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. Eur J Pharm Biopharm 2012; 80:544-52. [DOI: 10.1016/j.ejpb.2011.11.017] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2011] [Revised: 11/21/2011] [Accepted: 11/28/2011] [Indexed: 01/13/2023]
|
41
|
Di Tommaso C, Bourges JL, Valamanesh F, Trubitsyn G, Torriglia A, Jeanny JC, Behar-Cohen F, Gurny R, Möller M. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Eur J Pharm Biopharm 2012; 81:257-64. [PMID: 22445900 DOI: 10.1016/j.ejpb.2012.02.014] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2011] [Revised: 02/22/2012] [Accepted: 02/23/2012] [Indexed: 11/26/2022]
Abstract
Cornea transplantation is one of the most performed graft procedures worldwide with an impressive success rate of 90%. However, for "high-risk" patients with particular ocular diseases in addition to the required surgery, the success rate is drastically reduced to 50%. In these cases, cyclosporin A (CsA) is frequently used to prevent the cornea rejection by a systemic treatment with possible systemic side effects for the patients. To overcome these problems, it is a challenge to prepare well-tolerated topical CsA formulations. Normally high amounts of oils or surfactants are needed for the solubilization of the very hydrophobic CsA. Furthermore, it is in general difficult to obtain ocular therapeutic drug levels with topical instillations due to the corneal barriers that efficiently protect the intraocular structures from foreign substances thus also from drugs. The aim of this study was to investigate in vivo the effects of a novel CsA topical aqueous formulation. This formulation was based on nanosized polymeric micelles as drug carriers. An established rat model for the prevention of cornea graft rejection after a keratoplasty procedure was used. After instillation of the novel formulation with fluorescent labeled micelles, confocal analysis of flat-mounted corneas clearly showed that the nanosized carriers were able to penetrate into all corneal layers. The efficacy of a 0.5% CsA micelle formulation was tested and compared to a physiological saline solution and to a systemic administration of CsA. In our studies, the topical CsA treatment was carried out for 14 days, and the three parameters (a) cornea transparency, (b) edema, and (c) neovascularization were evaluated by clinical observation and scoring. Compared to the control group, the treated group showed a significant higher cornea transparency and significant lower edema after 7 and 13 days of the surgery. At the end point of the study, the neovascularization was reduced by 50% in the CsA-micelle treated animals. The success rate of cornea graft transplantation was 73% in treated animals against 25% for the control group. This result was as good as observed for a systemic CsA treatment in the same animal model. This new formulation has the same efficacy like a systemic treatment but without the serious CsA systemic side effects. Ocular drug levels of transplanted and healthy rat eyes were dosed by UPLC/MS and showed a high CsA value in the cornea (11710 ± 7530 ng(CsA)/g(tissue) and 6470 ± 1730 ng(CsA)/g(tissue), respectively). In conclusion, the applied formulation has the capacity to overcome the ocular surface barriers, the micelles formed a drug reservoir in the cornea from, where a sustained release of CsA can take place. This novel formulation for topical application of CsA is clearly an effective and well-tolerated alternative to the systemic treatment for the prevention of corneal graft rejection.
Collapse
|
42
|
Patois E, Capelle M, Palais C, Gurny R, Arvinte T. Evaluation of nanoparticle tracking analysis (NTA) in the characterization of therapeutic antibodies and seasonal influenza vaccines: pros and cons. J Drug Deliv Sci Technol 2012. [DOI: 10.1016/s1773-2247(12)50069-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Vacher G, Gremion C, Moser C, Stoffel S, Amacker M, Zurbriggen R, Gurny R, Borchard G. Virosomal C. albicans vaccine for vaginal application: formulation development and toxicity/immunogenicity studies. J Drug Deliv Sci Technol 2012. [DOI: 10.1016/s1773-2247(12)50071-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
44
|
de Valence S, Tille JC, Mugnai D, Mrowczynski W, Gurny R, Möller M, Walpoth BH. Long term performance of polycaprolactone vascular grafts in a rat abdominal aorta replacement model. Biomaterials 2012; 33:38-47. [DOI: 10.1016/j.biomaterials.2011.09.024] [Citation(s) in RCA: 295] [Impact Index Per Article: 24.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2011] [Accepted: 09/08/2011] [Indexed: 11/25/2022]
|
45
|
Eenschooten C, Vaccaro A, Delie F, Guillaumie F, Tømmeraas K, Kontogeorgis GM, Schwach-Abdellaoui K, Borkovec M, Gurny R. Novel self-associative and multiphasic nanostructured soft carriers based on amphiphilic hyaluronic acid derivatives. Carbohydr Polym 2012; 87:444-451. [DOI: 10.1016/j.carbpol.2011.08.004] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2011] [Revised: 05/24/2011] [Accepted: 08/03/2011] [Indexed: 10/17/2022]
|
46
|
Asmus LR, Gurny R, Möller M. Solutions as solutions – Synthesis and use of a liquid polyester excipient to dissolve lipophilic drugs and formulate sustained-release parenterals. Eur J Pharm Biopharm 2011; 79:584-91. [DOI: 10.1016/j.ejpb.2011.07.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2011] [Revised: 07/12/2011] [Accepted: 07/19/2011] [Indexed: 10/17/2022]
|
47
|
Gabriel D, Zuluaga MF, van den Bergh H, Gurny R, Lange N. It is all about proteases: from drug delivery to in vivo imaging and photomedicine. Curr Med Chem 2011; 18:1785-805. [PMID: 21466472 DOI: 10.2174/092986711795496782] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2010] [Accepted: 03/24/2011] [Indexed: 11/22/2022]
Abstract
Clinical studies provide overwhelming evidence for the importance of proteolytic imbalance and the upregulation of diverse protease classes in diseases such as cancer and arthritis. While the complex nature of proteolytic networks has hampered the development of protease inhibitors for these indications, aberrant enzyme activity could be successfully exploited for the development of proteasesensitive drug delivery systems and fluorescent in vivo imaging agents. More recently, these concepts have also been translated into photomedical applications to develop dual modality prodrugs for the simultaneous treatment and imaging of disease. After an introductory overview of proteases and their role in cancer, we present and discuss different strategies to exploit upregulated protease activity for the development of drug delivery systems, fluorescent in vivo reporter probes, and photosensitizer-prodrugs with respect to their potential and limitations. The main approaches used for targeting proteases in all three areas can be roughly divided into peptide-based and macromolecular strategies. Both involve the use of a short, peptide-based protease substrate, which is either directly tagged to the therapeutic agent or dye/quencher pair, or alternatively, serves as a linker between the polymeric carrier and a functional unit. In the latter case, the pharmacokinetic properties of peptide-based protease-sensitive prodrugs and imaging probes can be further ameliorated by the passive targeting capacity of macromolecular drug delivery systems for neoplastic and inflammatory lesions.
Collapse
|
48
|
Gurny R, Leroux JC. Editorial. Eur J Pharm Biopharm 2011; 79:1-2. [DOI: 10.1016/j.ejpb.2011.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
49
|
Patois E, Capelle MAH, Gurny R, Arvinte T. Stability of seasonal influenza vaccines investigated by spectroscopy and microscopy methods. Vaccine 2011; 29:7404-13. [PMID: 21803109 DOI: 10.1016/j.vaccine.2011.07.067] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2011] [Revised: 07/08/2011] [Accepted: 07/17/2011] [Indexed: 02/07/2023]
Abstract
The stability of different seasonal influenza vaccines was investigated by spectroscopy and microscopy methods before and after the following stress-conditions: (i) 2 and 4 weeks storage at 25°C, (ii) 1 day storage at 37°C and (iii) one freeze-thaw cycle. The subunit vaccine Influvac (Solvay Pharma) and the split vaccine Mutagrip (Sanofi Pasteur) were affected by all stresses. The split vaccine Fluarix (GlaxoSmithKline) was affected only by storage at 25°C. The virosomal vaccine Inflexal V (Berna Biotech) was stable after the temperature stresses but aggregated after one freeze-thaw cycle. This study provides new insights into commercial vaccines of low antigen concentration and highlights the importance of using multiple techniques to assess vaccine stability.
Collapse
|
50
|
Gurny R, Friess W. Unmet Needs in Protein Formulation Science. Eur J Pharm Biopharm 2011; 78:183. [DOI: 10.1016/j.ejpb.2011.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|